Objective. Previous studies have shown that the majority of patients with PMR have increased 18 F-fluorodeoxyglucose (FDG) uptake around the shoulders, hips and processes of the cervical and lumbar spine on PET. The specificity of these findings for PMR is, however, not known.
Introduction
PMR is a rather common inflammatory condition in patients over 50 years of age, characterized by bilateral shoulder and hip pain, neck pain, morning stiffness and raised inflammatory parameters in the blood. Treatment with low dose glucocorticoids gives rapid relief of symptoms and this empirical therapeutic strategy is often used as a diagnostic test. However, response to glucocorticoids is not specific for PMR and unnecessary treatment should be avoided. There is currently no specific test for the diagnosis of PMR. Hence, PMR remains a diagnosis made merely on clinical grounds. PMR can be found in association with GCA and can occur in patients with lateonset RA [13] .
In 2012, provisional classification criteria for PMR were published, based on results from a study in 125 PMR patients and 169 non-PMR subjects (mostly with new-onset RA or with shoulder conditions) [4] . According to these criteria, patients of at least 50 years old presenting with bilateral shoulder pain, not better explained by other conditions, can be classified as having PMR in the presence of morning stiffness of at least 45 min, elevated CRP and/ or ESR, and new onset hip pain. Nevertheless, the authors state explicitly that these criteria should not be used for diagnostic purposes. The sensitivity (68%) and specificity (78%) of these criteria were rather low, and adding ultrasound (evaluating bicipital tenosynovitis, subacromial and subdeltoid bursitis, trochanteric bursitis and glenohumeral and hip effusion) did not significantly modify the sensitivity (66%) or specificity (81%).
In 2007, our group published a prospective study on 35 patients with a diagnosis of isolated PMR who underwent a PET scan with 18 F-fluorodeoxyglucose (FDG-PET) at diagnosis (before start of glucocorticoid therapy) and at 3 and 6 months after treatment initiation [5] . At diagnosis, FDG uptake around the shoulders, hips and spinous processes of the lumbar or cervical vertebrae was noted in 94, 89 and 51% of patients, respectively. In this study, however, no control patients were included, so specificity of these FDG-PET findings could not be determined.
In the present study, we therefore prospectively performed FDG-PET scans in 100 consecutive patients with a clinical suspicion of PMR, prior to the start of glucocorticoid treatment and before final confirmation of PMR. This study design enabled us to calculate sensitivities, specificities, negative predictive values (NPV) and positive predictive values (PPV) for different combinations of clinical symptoms and FDG-PET findings for diagnosing PMR.
Methods

Patient population
Between August 2012 and November 2015, we prospectively included 100 consecutive patients admitted to the Department of General Internal Medicine of the Leuven University Hospitals, with a clinical presentation comprising PMR as differential diagnosis. All patients gave written informed consent before inclusion. One patient was excluded, because the clinical picture was never compatible with PMR but rather with isolated GCA; patients with predominant PMR but additional GCA symptoms were allowed in the study. CRP and ESR were determined in every patient; other tests (such as autoimmune serology, chest X-ray, abdominal US, X-ray or US of the shoulders) were done if deemed necessary. All patients underwent FDG-PET scan as soon as possible, prior to steroid treatment. At inclusion, and before FDG-PET, the treating clinician scored the clinical probability of PMR on a five-point visual analogue scale (clinical score 15 with increasing probability for PMR based on clinical symptoms and laboratory values).
The gold standard final diagnoses were those that were withheld by an experienced clinician (D.B., L.H., S.V.) 6 months after inclusion in the study, taking into account all available information (clinical data and evolution, radiological, biochemical, PET), but blinded for the initial clinical score. This study and the informed consent forms were approved by the Ethical Committee of the Leuven University Hospitals. 18 
F-FDG-PET
Patients were fasted for at least 6 h before intravenous injection of 45 MBq/kg of 18 F-FDG, and blood glucose levels were checked in all patients. A whole body PET emission scan was performed 4560 min after tracer administration. PET scans were performed on an ECAT HR + PET camera, Hirez Biograph 16 PET/CT or Truepoint Biograph 40 PET/CT (Siemens, Knoxville, TN, USA). On the PET/CT systems, either a low-dose non-diagnostic CT scan or a diagnostic CT scan with oral and intravenous contrast was performed immediately before PET acquisition.
Non-attenuation-corrected PET images, available for all included patients, were re-evaluated visually by two independent specialists in nuclear medicine (O.G., K.G.), who were blinded for all other patient information. FDG-PET uptake was assessed for 12 skeletal regions (cervical spinous processes, lumbar spinous processes, left and right sternoclavicular joint, left and right ischial tuberosity, left and right greater trochanter, left and right hip, and left and right shoulder), and scored on a three-point scoring system: 0 (no FDG uptake), 1 (moderate FDG uptake, less than liver uptake) or 2 (intense FDG uptake, equal or more than liver uptake). In the case of discrepancy between readers, a consensus reading was performed. For symmetrical skeletal regions (sternoclavicular joints, ischial tuberosities, greater trochanters, hips and shoulders), scores from both sides were summed. Summed scores of 2 or less were considered to be negative, while score of 3 or 4 were considered positive. For the cervical and lumbar spinous processes, scores of 0 and 1 were considered negative and only score 2 as positive. Furthermore, a total skeletal score was calculated for every patient, by summing the individual scores at the 12 different skeletal sites (total 024).
Additionally, PET scans were scored at four different vascular regions (thoracic aorta, abdominal aorta, subclavian arteries and carotid arteries), with the same visual three-point scoring system (0, 1 and 2). Examples of typical PET scan findings in PMR patients are given in Fig. 1 .
Statistical analyses
Statistical analyses were performed using Statview 5.0 software (SAS Institute, Cary, NC, USA) and SPSS Statistics version 20 (IBM Corp., Armonk, NY, USA). Results were compared using chi-square statistics, https://academic.oup.com/rheumatology
Fisher's exact test or the MannWhitney U test, as appropriate. For all analyses, a two-tailed P < 0.05 was considered significant. The sensitivity and specificity of FDG uptake at different skeletal sites and their combinations were calculated. Receiver operating characteristic (ROC) curves were built for the clinical score and the total skeletal score, and threshold values were determined for optimal sensitivity and specificity. A multivariable logistic regression analysis was performed to examine the conditional effects of both clinical score and total skeletal score on the diagnosis of PMR.
Results
Patient characteristics
A final diagnosis of isolated PMR was made in 67 patients, and another condition was diagnosed in the remaining 32 patients. The final diagnosis was the one made by an experienced clinician after at least 6 months' follow-up.
Diagnoses made in non-PMR patients were: rotator cuff pathology (n = 8), spontaneous resolution (n = 8), OA (n = 5), seronegative RA (n = 3) and adult onset Still's disease, FM, late onset X-linked hypogammaglobulinaemia, lupus, PM, osteoporosis, paraneoplastic syndrome and spondylarthropathy in one patient each. Clinical characteristics of the patients are shown in Table 1 .
There was no difference in age or gender between patients with PMR and patients with other diagnoses. Sixteen per cent of PMR patients and 9% of non-PMR patients had a previous history of PMR or GCA [non-significant (NS)]. The majority of PMR and non-PMR patients complained of shoulder pain (96% vs 87%, NS). There was an important difference in reported hip girdle pain and the combination of hip and shoulder girdle pain between PMR and non-PMR patients (87% vs 53%, P = 0.0004, and 82% vs 47%, P < 0.0004, respectively). Morning stiffness (78% vs 50%, P = 0.005) and weight loss (48% vs 19%, P = 0.004) were also more frequent in PMR patients as compared with non-PMR patients. There was no difference in fever, back pain and pain or swelling of other joints.
ESR [59 (interquartile range (IQR): 3778) vs 33 (IQR: 2079) mm/1 h, P = 0.05] and CRP levels [52.3 (IQR: 18.781.9) vs 8.3 (IQR: 3.440.9) mg/l, P = 0.0002] were significantly higher in PMR patients, as were alpha1-globulin (P = 0.0005) and alpha2-globulin (P = 0.0007) levels. There was no difference in haemoglobin or gammaglobulin levels.
The time between the onset of symptoms and first assessment in our clinic with subsequent FDG-PET-scan was shorter in PMR patients than in non-PMR patients (45 vs 120 days, P = 0.014). As could be expected, glucocorticoid therapy was more often started in PMR patients and was much more efficacious in PMR patients than in the non-PMR group (98% of success rate vs 33%, P < 0.0001).
Patients with a higher degree of suspicion (clinical score) for the diagnosis of PMR were more likely to receive a final diagnosis of PMR (see Table 1 ). Sixty-seven per cent of PMR patients had a high degree of suspicion (defined as a score of 4 or 5) for PMR, compared with only 13% of non-PMR patients; on the other hand, 56% of non-PMR patients had a low degree of suspicion for with proven PMR at final diagnosis, but with a maximum total skeletal score of 24. SUV: standardized uptake value.
PMR compared with 12% of PMR patients (P < 0.0001). The median clinical score was 4 (IQR: 35) in patients with PMR vs 2 (IQR: 13) in patients without PMR (P < 0.0001) ( Fig. 2A) . With an increasing clinical score, the sensitivity for the diagnosis of PMR decreased, while the specificity increased (Table 2 ). In the ROC analysis (Fig. 3) , the area under the curve for the clinical score was 0.830 (0.04) (P < 0.0001). The ideal clinical score for differentiation between PMR and non-PMR was 4, with a sensitivity of 67.2%, a specificity of 87.5%, a PPV of 91.8% and an NPV of 56.0%.
FDG-PET results
FDG-PET results for PMR and non-PMR patients are shown in supplementary Table S1, available at Rheumatology Online. PMR patients had significantly more intense FDG uptake in all predefined skeletal regions compared with non-PMR patients, with the exception of the shoulders.
FDG-PET-scan scores for the four vascular regions did not differ significantly between PMR and non-PMR patients (supplementary Table S2 , available at Rheumatology Online).
Overall, a vascular FDG uptake score of 2 in at least one large vessel was observed in 15% of PMR patients and 6% of non-PMR patients (NS). FDG uptake in the carotid arteries and in the thoracic aorta was seen in some PMR patients, but never in non-PMR patients. An increased FDG uptake in the abdominal aorta was never seen, whereas FDG uptake in the subclavian arteries was nonspecific for PMR. Of the 12 patients with a vascular FDG uptake score of at least 2, two were diagnosed with GCA based on positive temporal artery biopsy, and then the dose of steroids was increased accordingly. Table 3 shows the sensitivities, specificities, PPV and NPV of for a positive FDG-PET-scan score for the diagnosis of PMR in one region or for a combination of skeletal regions. None of the individual skeletal regions performed well as a diagnostic tool on its own because acceptable specificity was associated with worse sensitivity and vice versa. Several possible combinations had a specificity and PPV of 100%, but a sensitivity and NPV that were so low that they make the test unfit for diagnostic purposes (see Table 3 ). None of the skeletal combinations had a diagnostic accuracy better than the individual skeletal regions. As expected, adding the shoulders to any score did not significantly change the sensitivity or specificity (data not shown). The total skeletal score was 21 (IQR: 1822.75) in patients with PMR as compared with 12 (IQR: 9.513.5) in patients without PMR (P < 0.0001) (Fig. 2B) .
In the ROC analysis, the area under the curve for the total skeletal score was 0.905 (0.03) (P < 0.0001) (Fig. 3) . The ideal total skeletal score for differentiation between PMR and non-PMR was 16, with a sensitivity of 85.1% and a specificity of 87.5% (PPV 93.4%, NPV 73.7%).
The three included patients with RA had clinical scores of 2, 3 and 4, respectively, and a total skeletal score of 10 each. Especially shoulders and major trochanters took up FDG; sternoclavicular joints were negative in all three cases.
In a multivariable analysis, both clinical score [P = 0.002; odds ratio (OR) = 2.5, 95% CI: 1.4, 4.5] and the FDG-PET total skeletal score (P < 0.0001; OR = 1.35, 95% CI: 1.17, 1.55) were independently associated with a diagnosis of PMR.
Discussion
The main purpose of this prospective study was to determine the diagnostic performance of formerly described FDG-PET findings in patients with PMR. Previous PET studies from our and other groups have demonstrated an increased FDG uptake at the shoulders, hips and cervical or lumbar spinous processes in patients with PMR [57] . Increased FDG uptake at other articulations, such as the sternoclavicular joints, has also been reported [8] . However, sensitivities and especially specificities of different patterns of FDG uptake in PMR were not known until now.
Our study population consisted of 99 patients for whom the treating physician considered PMR as a possible diagnosis. This clinical suspicion of PMR was confirmed in 67 patients, after careful follow-up of at least 6 months. In the remaining 32 patients, a diagnosis other than PMR was made. An important number of our non-PMR patients suffered from local shoulder problems (periarthritis scapulohumeralis) or OA. In 25% of non-PMR patients the symptoms disappeared spontaneously. Shoulder pain was a very bad discriminator between PMR and non-PMR, while hip girdle pain and morning stiffness of > 30 min duration were significantly more prevalent in PMR patients.
As could be expected, the diagnosis was confirmed more frequently in those patients with a high degree of clinical suspicion. Nevertheless, the diagnosis of PMR was also made in eight patients (12%) with a low degree of clinical suspicion (clinical score 1 or 2/5), and in these cases, FDG-PET contributed to making the diagnosis, with a total skeletal score of >16 in 6 out of 8 patients. On the other hand, another condition was diagnosed in four patients with high degree of clinical suspicion for PMR [more specifically, degenerative shoulder pathology (n = 2), seronegative RA (n = 1) and self-limiting symptoms without specific diagnosis (n = 1)]. In these cases, FDG-PET did not provide an alternative diagnosis. Of the 24 patients with an intermediate degree of suspicion (clinical score 3/5), 10 turned out to have another condition than PMR. These data corroborate previous findings that in a substantial number of patients, one cannot rely solely on clinical (and inflammatory) parameters to make a diagnosis of PMR, but that additional tests are helpful. Our data are in accordance with the findings of the EULAR and the ACR Collaborative Initiative [4] . Our results demonstrate that FDG-PET may be more suited than US as an additional test for the diagnosis of PMR. Increased FDG uptake at the shoulders was seen in 97% of PMR patients, but this finding was highly non-specific (specificity only 6.3%). This reflects the very unspecific nature of shoulder pain as a clinical sign for PMR. The opposite was true for a clearly increased FDG uptake at the lumbar spinous processes: this finding alone had a specificity of 100%, but was much less sensitive (only 46.3%).
In the current study, we developed a total skeletal score, based on a three-point scoring system for 12 articular regions resulting in a total score ranging from 0 (no FDG uptake in any region) to 24 (FDG uptake scored 2 in every region). This scoring system can be regarded as the counterpart of the total vascular score that we developed previously for vascular FDG uptake in GCA patients [9] . This newly developed total skeletal score discriminates very well between PMR and non-PMR patients, with an optimal cut-off value of 16 (sensitivity 85.1%, specificity 87.5%). These values for sensitivity and specificity were higher than those of the clinical judgement, based on the assessment of the treating physician before the FDG-PET was performed: an ideal clinical score of 4 or more had the same specificity but a sensitivity of only 67.2%.
A somewhat similar approach-but in a retrospective manner-was followed by Sondag et al. [10] . They analysed 17 hotspots on PET scans performed in 50 patients with a diagnosis of PMR and 53 patients with a neoplasm as a control group (shoulders, acromioclavicular joints,
FIG. 3 Receiver operating characteristic curves for the diagnosis of PMR
Receiver operating characteristic curves were built for the clinical score and the total skeletal score in patients with PMR (n = 67) and in non-PMR patients (n = 32). The area under the curve for the clinical score was 0.830 ± 0.04 (P < 0.0001) and for the total skeletal score was 0.905 ± 0.03 (P < 0.0001).
https://academic.oup.com/rheumatology sternoclavicular joints, spinous processes, greater trochanters, hips, ischial tuberosities, symphysis pubis and iliopectineal bursae). The presence of three or more sites with significant uptake was correlated with the diagnosis of PMR with a sensitivity of 74% and specificity of 79%. Major drawbacks of their study were the retrospective nature and the fact that, in contrast to our study, the research question did not reflect the real life clinical dilemma, as control patients were oncological cases without any clinical symptoms mimicking PMR. Moreover, only 38 patients had isolated PMR (five had associated GCA and seven were categorized as PMR-like associated with other diseases) and 28 of the PMR patients were already being treated with glucocorticoids at the moment of PET scanning.
Our findings showing that only 15% of PMR patients had an increased FDG uptake in the larger thoracic vessels, compared with 6% of control patients (not significantly different) may seem different from the 31% of PMR patients with vascular FDG uptake in our former PMR study [5] . This can be explained because in the current study, a vascular uptake of at least 2 (equal or more than liver uptake) was required, compared with a score of only 1 in the previous study. A moderate FDG uptake in the subclavian arteries, scored 1, was frequently seen, also in non-PMR patients. This is a non-specific finding, probably due to blood pool activity (and not activity in the vessel wall) which may be explained by a too short interval between tracer administration and imaging in some of the scans [11] as well as by limited resolution of FDG-PET.
An additional advantage of performing a whole-body PET scan in patients suspected of PMR, may be the exclusion of other conditions, especially occult malignancies that can present with a PMR-like image. In our non-PMR group, one patient was diagnosed with a carcinoid neoplasm (also visible on PET scan), and symptoms were explained as a paraneoplastic manifestation.
Several authors retrospectively compared FDG-PET findings in PMR patients and in RA patients [12, 13] . This differential diagnosis can indeed be challenging, especially in elderly patients and if antibodies against CCP are negative. Yamashita et al. [12] studied 16 patients with PMR and 16 patients with rheumatoid arthritis. FDG uptake measured as standardized uptake values at ischial tuberosities, greater trochanters and spinous processes was significantly higher in PMR than in RA patients. Takahashi et al. [13] analysed FDG-PET/CT findings in 10 patients with elderly onset RA and 27 patients with PMR. No significant differences were detected for FDG uptake at the shoulders and the hips, but the presence of focal uptake anterior to the hip joint, indicating iliopectineal bursitis, was limited to the PMR group. Specific uptake patterns at the shoulders were observed in each group: focal and non-linear in PMR vs circular and linear in the RA patients. High sensitivity (92.6%) and specificity (90%) were observed for PMR diagnoses when at least three of the following five items were present: characteristic PET findings at the shoulders, the presence of iliopectineal bursitis, FDG uptake in ischial tuberosities, FDG uptake at spinous processes and lack of FDG uptake in the wrists. In our experience, FDG uptake patterns at the shoulders are similar in PMR and RA patients. Wakura et al. [14] prospectively compared abnormal FDG accumulation sites between 15 PMR patients and seven elderly onset rheumatoid arthritis patients. Abnormal FDG accumulation at different muscular and skeletal sites was significantly more frequent in PMR patients. The number of RA patients in our control population was too low to justify conclusions (n = 3), but the total skeletal score was 10 in each of them, well below 16. In the majority of elderly RA patients, the presence of CCP antibodies allows a correct diagnosis, and hence these patients did not enter our study.
We chose to perform FDG-PET scans before the start of glucocorticoid therapy, since glucocorticoids may hamper the interpretation of PET results by reducing sensitivity because of suppressed disease activity [15] . To our knowledge, there are no studies in PMR patients comparing FDG-PET findings before and after the start of glucocorticoid treatment, but extrapolating data from GCA cohorts [11] and given lower sensitivities and specificities when patients on glucocorticoids were included [10] , it seems wise to perform PET scintigraphy before therapy is started.
This study has some limitations. First of all, part of the FDG-PET scans were performed on a stand-alone PETsystem with lower resolution and sensitivity compared with current PET-CT systems. Nevertheless, we believe this will not have influenced the results, because the visual scoring system was based on an intra-patient comparison with the liver as a reference. Second, we performed only visual analysis of non-attenuation-corrected PET images. To our knowledge, however, it has never been shown that quantification of FDG uptake at different predefined locations would be better than the semi-quantitative visual scoring system we used in this study. Thirdly, because all FDG-PET scans in the current study have been performed on patients that were not on steroids, the performance of FDG-PET from the current study cannot be extrapolated to patients that have already been treated with steroids. The fact that PET results (but not the total skeletal score!) were known to the clinical investigators by the time they made the final diagnosis can be regarded as a limitation of our study. In our centre, however, it reflects daily clinical practice, as PET scan has become a routine investigation in patients suspected of PMR, since previous studies from our group and others have shown that a combination of an increased FDG uptake in the shoulders, hips and cervical or lumbar spinous processes is frequently found in PMR patients [57] .
We do not recommend the use of FDG-PET scan in every patient suspected of PMR, since this technique is not readily available everywhere and costs may be high, depending on the country. In patients with very typical clinical pictures, treatment can be started based on the combination of compatible clinical symptoms and serum markers of inflammation alone. If the clinical picture has some atypical elements, or if inflammatory parameters are not as high as expected, FDG-PET scan may be a reliable aid.
Conclusions
Performing an FDG-PET scan prior to the start of glucocorticoid treatment improves the diagnostic accuracy in a patient with suspicion of PMR. A total skeletal score of at least 16 has a sensitivity of 85.1% and a specificity of 87.5% for the diagnosis of PMR, outperforming the 2012 Provisional Classification Criteria.
